Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity.

Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med (2010) 7.31

Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila) (2011) 2.62

Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer (2011) 2.41

Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid Redox Signal (2010) 1.77

Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability. PLoS One (2014) 1.57

Quantifying nuclear p65 as a parameter for NF-κB activation: Correlation between ImageStream cytometry, microscopy, and Western blot. Cytometry A (2011) 1.27

Radiation, inflammation, and immune responses in cancer. Front Oncol (2012) 1.25

Targeting inflammatory pathways for tumor radiosensitization. Biochem Pharmacol (2010) 1.22

Curcumin modulates nuclear factor kappaB (NF-kappaB)-mediated inflammation in human tenocytes in vitro: role of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem (2011) 1.15

Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways. Carcinogenesis (2011) 1.13

New perspectives of curcumin in cancer prevention. Cancer Prev Res (Phila) (2013) 1.05

Curcumin and synthetic analogs induce reactive oxygen species and decreases specificity protein (Sp) transcription factors by targeting microRNAs. BMC Cancer (2012) 1.04

Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy. Chin Med (2011) 1.03

The nontoxic natural compound Curcumin exerts anti-proliferative, anti-migratory, and anti-invasive properties against malignant gliomas. BMC Cancer (2010) 0.98

Curcumin-the paradigm of a multi-target natural compound with applications in cancer prevention and treatment. Toxins (Basel) (2010) 0.93

Therapeutic potential of curcumin in gastrointestinal diseases. World J Gastrointest Pathophysiol (2011) 0.91

Nutraceutical use in late-stage cancer. Cancer Metastasis Rev (2010) 0.90

Potential targets for colorectal cancer prevention. Int J Mol Sci (2013) 0.89

Chromatin-regulating proteins as targets for cancer therapy. J Radiat Res (2014) 0.88

Biological and therapeutic activities, and anticancer properties of curcumin. Exp Ther Med (2015) 0.86

Curcumin attenuates radiation-induced inflammation and fibrosis in rat lungs. Korean J Physiol Pharmacol (2013) 0.85

The mismatch repair system modulates curcumin sensitivity through induction of DNA strand breaks and activation of G2-M checkpoint. Mol Cancer Ther (2010) 0.83

Clinical comparison of dose calculation using the enhanced collapsed cone algorithm vs. a new Monte Carlo algorithm. Strahlenther Onkol (2011) 0.82

Nano-curcumin inhibits proliferation of esophageal adenocarcinoma cells and enhances the T cell mediated immune response. Front Oncol (2013) 0.82

Curcumin potentiates rhabdomyosarcoma radiosensitivity by suppressing NF-κB activity. PLoS One (2013) 0.82

NF-κB pathway in colitis-associated cancers. Transl Gastrointest Cancer (2013) 0.81

A functional biological network centered on XRCC3: a new possible marker of chemoradiotherapy resistance in rectal cancer patients. Cancer Biol Ther (2015) 0.80

Inhibition of radiation-induced DNA repair and prosurvival pathways contributes to vorinostat-mediated radiosensitization of pancreatic cancer cells. Pancreas (2010) 0.80

Zerumbone increases oxidative stress in a thiol-dependent ROS-independent manner to increase DNA damage and sensitize colorectal cancer cells to radiation. Cancer Med (2014) 0.80

Prevention and Treatment of Colorectal Cancer by Natural Agents From Mother Nature. Curr Colorectal Cancer Rep (2013) 0.80

Curcumin suppresses colon cancer cell invasion via AMPK-induced inhibition of NF-κB, uPA activator and MMP9. Oncol Lett (2016) 0.78

Curcuma Contra Cancer? Curcumin and Hodgkin's Lymphoma. Cancer Growth Metastasis (2013) 0.78

Alpha-tomatine attenuation of in vivo growth of subcutaneous and orthotopic xenograft tumors of human prostate carcinoma PC-3 cells is accompanied by inactivation of nuclear factor-kappa B signaling. PLoS One (2013) 0.78

Differential activation of NF-κB and nitric oxide in lymphocytes regulates in vitro and in vivo radiosensitivity. Mutat Res (2010) 0.77

Antioxidant Intake and Antitumor Therapy: Toward Nutritional Recommendations for Optimal Results. Oxid Med Cell Longev (2015) 0.77

A neutraceutical by design: the clinical application of curcumin in colonic inflammation and cancer. Scientifica (Cairo) (2012) 0.76

Properties of lewis lung carcinoma cells surviving curcumin toxicity. J Cancer (2011) 0.76

Da0324, an inhibitor of nuclear factor-κB activation, demonstrates selective antitumor activity on human gastric cancer cells. Drug Des Devel Ther (2016) 0.75

Relationship and interactions of curcumin with radiation therapy. World J Clin Oncol (2016) 0.75

Suppression of NF-κB activity by mutant IκBα: A molecular target for radiosensitization of adenoid cystic carcinoma. Oncol Lett (2013) 0.75

Enhanced autophagy in colorectal cancer stem cells does not contribute to radio-resistance. Oncotarget (2016) 0.75

Natural Agents Used in Chemoprevention of Aerodigestive and GI Cancers. Curr Pharmacol Rep (2016) 0.75

NOX4-mediated ROS production induces apoptotic cell death via down-regulation of c-FLIP and Mcl-1 expression in combined treatment with thioridazine and curcumin. Redox Biol (2017) 0.75

Involvement of miR-155/FOXO3a and miR-222/PTEN in acquired radioresistance of colorectal cancer cell line. Jpn J Radiol (2017) 0.75

Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med (2004) 25.68

Missing pieces in the NF-kappaB puzzle. Cell (2002) 17.83

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA (2006) 15.65

TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science (1996) 11.29

Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 8.79

Nuclear factor-kappaB: the enemy within. Cancer Cell (2004) 6.86

Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol (2005) 6.00

NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol (1999) 5.98

Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med (1999) 4.40

Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci U S A (1997) 4.07

Dose escalation of a curcuminoid formulation. BMC Complement Altern Med (2006) 3.59

Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem (1995) 2.60

Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFkappaB activation in primary hippocampal neurons. J Biol Chem (1999) 2.27

Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer (2004) 2.19

Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene (2001) 2.17

Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology (1996) 2.16

Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood (2003) 2.09

Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol (2005) 1.94

Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) suppresses NF-kappaB activation and NF-kappaB-regulated gene products through modulation of p65 and IkappaBalpha kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents. J Biol Chem (2006) 1.90

Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev (2005) 1.83

Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol (2001) 1.77

Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys (2001) 1.67

Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res (2007) 1.60

Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol (2006) 1.57

Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol (2006) 1.56

Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clin Cancer Res (2008) 1.55

ch-IAP1, a member of the inhibitor-of-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein. Mol Cell Biol (1997) 1.49

Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol (2007) 1.43

Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene (2004) 1.42

Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma. Cancer (2003) 1.36

Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer (2005) 1.31

Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients. Int J Radiat Oncol Biol Phys (2004) 1.31

Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Anticancer Drugs (1997) 1.27

Increased nuclear factor-kB activation in human colorectal carcinoma and its correlation with tumor progression. Anticancer Res (2004) 1.27

Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol (2006) 1.21

Increased expression of RelA/nuclear factor-kappa B protein correlates with colorectal tumorigenesis. Oncology (2003) 1.21

Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2006) 1.21

New mechanisms and therapeutic potential of curcumin for colorectal cancer. Mol Nutr Food Res (2008) 1.19

Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. Radiother Oncol (1999) 1.19

Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-kappaB-regulated gene expression and up-regulation of apoptosis. J Biol Chem (2004) 1.13

Retracted Curcumin (diferuloylmethane) inhibits constitutive active NF-kappaB, leading to suppression of cell growth of human T-cell leukemia virus type I-infected T-cell lines and primary adult T-cell leukemia cells. Int J Cancer (2006) 1.02

Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agents. J Cell Physiol (2003) 1.01

Enhanced radiosensitivity by inhibition of nuclear factor kappa B activation in human malignant glioma cells. Int J Radiat Biol (1997) 0.93

Upregulation of cyclooxygenase-2 is accompanied by increased expression of nuclear factor-kappa B and I kappa B kinase-alpha in human colorectal cancer epithelial cells. Br J Cancer (2003) 0.90

Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human colorectal carcinoma tissue. World J Gastroenterol (2004) 0.90

Constitutive NF-kappaB activity in colorectal cancer cells: impact on radiation-induced NF-kappaB activity, radiosensitivity, and apoptosis. Neoplasma (2006) 0.90

Comparison of the anti-proliferation and apoptosis-induction activities of sulindac, celecoxib, curcumin, and nifedipine in mismatch repair-deficient cell lines. J Formos Med Assoc (2004) 0.85

Intravenous injection of oligodeoxynucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice. Gene Ther (2001) 0.83

Adenovirus-mediated gene transduction of truncated I kappa B alpha enhances radiosensitivity in human colon cancer cells. Cancer Sci (2003) 0.82

Bioavailability of curcumin: problems and promises. Mol Pharm (2007) 8.72

Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med (2010) 7.31

Inflammation and cancer: how hot is the link? Biochem Pharmacol (2006) 5.17

Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol (2007) 5.13

Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res (2008) 4.29

Nuclear factor-kappaB: its role in health and disease. J Mol Med (Berl) (2004) 4.01

Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett (2008) 3.61

Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol (2008) 3.45

Cancer is a preventable disease that requires major lifestyle changes. Pharm Res (2008) 3.28

Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol (2009) 3.22

Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett (2008) 3.14

Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res (2007) 2.95

Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol (2008) 2.95

Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J (2009) 2.89

Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol (2007) 2.70

Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol (2005) 2.62

Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev (2010) 2.57

Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta (2010) 2.55

Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci (2006) 2.44

Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol (2003) 2.44

"Spicing up" of the immune system by curcumin. J Clin Immunol (2007) 2.43

Curcumin: getting back to the roots. Ann N Y Acad Sci (2005) 2.42

Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J (2012) 2.42

Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology (2002) 2.38

Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood (2002) 2.37

Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys (2012) 2.29

Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol (2002) 2.27

Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol (2011) 2.24

Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24

Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol (2003) 2.22

Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol (2012) 2.22

Reactive oxygen intermediates in TNF signaling. Mol Immunol (2002) 2.20

Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer (2004) 2.19

Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med (Maywood) (2008) 2.19

A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. J Clin Invest (2006) 2.15

Retracted Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol (2009) 2.12

Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle (2008) 2.10

Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood (2003) 2.09

Reduced risk of colorectal cancer with use of oral bisphosphonates: a systematic review and meta-analysis. J Clin Oncol (2012) 2.09

Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer (2013) 2.09

Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal (2012) 2.05

Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha and serine phosphorylation of p65: evidence for the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase. J Biol Chem (2003) 2.05

Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann N Y Acad Sci (2005) 2.05

The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta (2012) 2.05

Staphylococcal complement evasion by various convertase-blocking molecules. J Exp Med (2007) 2.03

NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem (2009) 2.03

Role of curcumin in cancer therapy. Curr Probl Cancer (2007) 2.00

Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood (2006) 2.00

Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood (2007) 1.99

Cancer prevention with natural compounds. Semin Oncol (2010) 1.98

Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res (2007) 1.98

An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD). Hum Mol Genet (2010) 1.95

Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol (2005) 1.94

Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIB and dectin-1. Nat Med (2012) 1.93

A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res (2006) 1.92

TNF: a master switch for inflammation to cancer. Front Biosci (2008) 1.91

Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem (2003) 1.91

Anticancer potential of silymarin: from bench to bed side. Anticancer Res (2007) 1.91

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res (2004) 1.90

Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) suppresses NF-kappaB activation and NF-kappaB-regulated gene products through modulation of p65 and IkappaBalpha kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents. J Biol Chem (2006) 1.90

Role of chemopreventive agents in cancer therapy. Cancer Lett (2004) 1.88

Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res (2008) 1.88

Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer (2007) 1.86

Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis. Gastrointest Endosc (2011) 1.83

Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis. Neurosurgery (2002) 1.83

Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res (2006) 1.82

Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis (2002) 1.79

CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int J Cancer (2009) 1.79

Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res (2002) 1.78

Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis (2007) 1.78

Does neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival? Ann Surg Oncol (2008) 1.77

Ursolic acid inhibits nuclear factor-kappaB activation induced by carcinogenic agents through suppression of IkappaBalpha kinase and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1. Cancer Res (2003) 1.74

Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci (2013) 1.72

Retracted Cyclodextrin-complexed curcumin exhibits anti-inflammatory and antiproliferative activities superior to those of curcumin through higher cellular uptake. Biochem Pharmacol (2010) 1.72

Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol (2012) 1.72

Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem (2004) 1.66

Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol (2008) 1.65

Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res (2008) 1.63

Cigarette smoke condensate activates nuclear transcription factor-kappaB through phosphorylation and degradation of IkappaB(alpha): correlation with induction of cyclooxygenase-2. Carcinogenesis (2002) 1.63

Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep (2011) 1.62

Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer (2010) 1.62

Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells. Mol Cancer Res (2007) 1.61

RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem (2004) 1.61

The dosimetric feasibility of gold nanoparticle-aided radiation therapy (GNRT) via brachytherapy using low-energy gamma-/x-ray sources. Phys Med Biol (2009) 1.61

Natural products as a gold mine for arthritis treatment. Curr Opin Pharmacol (2007) 1.59

Modulation of in vivo tumor radiation response via gold nanoshell-mediated vascular-focused hyperthermia: characterizing an integrated antihypoxic and localized vascular disrupting targeting strategy. Nano Lett (2008) 1.58

Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene (2004) 1.58

Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res (2008) 1.58

Nuclear factor-kappaB activation: a question of life or death. J Biochem Mol Biol (2002) 1.58